William Blair Increases Earnings Estimates for Genmab A/S
William Blair upped their FY2028 EPS estimates for Genmab A/S in a research note issued on Monday, March 10th. William Blair ...
Fintel on MSN2d
William Blair Upgrades Genmab A (GMAB)
Fintel reports that on March 11, 2025, William Blair upgraded their outlook for Genmab A (NasdaqGS:GMAB) from Market Perform ...
William Blair upgrades Genmab with focus now on pipeline
William Blair analyst Matthew Phipps last night upgraded Genmab (GMAB) to Outperform from Market Perform without a price target. after the ...
Genmab upgraded to Outperform from Market Perform at William Blair
William Blair upgraded Genmab (GMAB) to Outperform from Market Perform.Optimize Your Investment Research with SparkEffectively assess a stock's ...
Fierce Biotech4d
J&J opts out of licensing Genmab's Darzalex challenger after look at phase 1/2 data
Johnson & Johnson is dropping a partnership with Genmab centered around a CD38 monoclonal antibody, prompting the latter ...
Genmab A/S (NASDAQ:GMAB) Price Target Cut to $45.00 by Analysts at Truist Financial
Genmab A/S (NASDAQ:GMAB – Free Report) had its price target decreased by Truist Financial from $50.00 to $45.00 in a report ...
Genmab sinks as J&J opts not to develop Darzalex successor; stock upgraded
Genmab (CSE:GMAB) (NASDAQ:GMAB) announced on Monday, March 10, that Johnson&Johnson (NYSE:JNJ) has chosen not to proceed with the development of GEN3014 (HexaBody-CD38), a next-gen version of their ...
Investing2d
Genmab A/S announces board constitution and equity grants
Despite the setback with HexaBody-CD38, William Blair upgraded Genmab’s stock rating from Market Perform to Outperform, citing the company’s promising pipeline, including treatments like ...
Investing3d
Genmab stock rating upgraded to Outperform by William Blair
On Tuesday, William Blair analysts revised their stance on Genmab A/S (NASDAQ:GMAB), upgrading the stock from Market Perform to Outperform. The upgrade followed Genmab’s announcement on Monday ...
Investing2d
Genmab A/S announces board constitution and equity grants
Despite the setback with HexaBody-CD38, William Blair upgraded Genmab’s stock rating from Market Perform to Outperform, citing the company’s promising pipeline, including treatments like Epkinly and ...